Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 6/20 | 0.40 |
| ▸ | CTSL | P07711 | 4/20 | 0.40 |
| ▸ | CTSB | P07858 | 3/20 | 0.40 |
| ▸ | REN | P00797 | 3/20 | 0.39 |
| ▸ | PSMB5 | P28074 | 7/20 | 0.36 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.35 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.35 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.35 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.35 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.35 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.35 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.35 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.35 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.35 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.35 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.35 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.35 |
| ▸ | PSMB3 | P49720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7048372 | 0.88 | FPR2 (0.52) | FPR2CTSSCTSLCTSBREN | |
| SCHEMBL6464251 | 0.84 | REN (0.41) | CTSSCTSLCTSBREN | |
| SCHEMBL7183373 | 0.83 | CTSS (0.55) | CTSSCTSLCTSB | |
| SCHEMBL7043177 | 0.81 | FPR2 (0.53) | FPR2CTSSCTSLCTSBPSMB5 | |
| SCHEMBL7044867 | 0.74 | CTSS (0.48) | CTSSCTSLCTSBREN | |
| SCHEMBL7109606 | 0.74 | CTSS (0.48) | CTSSCTSLCTSBREN | |
| SCHEMBL7049025 | 0.74 | CTSS (0.64) | CTSSCTSLCTSBREN | |
| SCHEMBL7047934 | 0.71 | CTSS (0.46) | CTSSCTSLCTSBREN | |
| SCHEMBL6467503 | 0.71 | REN (0.33) | REN | |
| SCHEMBL7043449 | 0.70 | CTSS (0.63) | CTSSCTSLCTSBREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1516877-A1 | Amine derivatives as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2005-03-23 | — | — | EP | disclosed |
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | US | disclosed |
| US-6576630-B1 | Alkanoyl substituted benzooxazoles or naphthooxazoles | AXYS PHARMACEUTICALS, INC. | 2003-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232864-A1 | Novel Compounds and compositions as protease inhibitors | SERPINB1, CTRL, CTSZ | FPR2 2099/4885CTSS 9/4885CTSL 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.